Selective estrogen receptor modulators: an update on recent clinical findings

Area of Science:

• Endocrinology and Pharmacology
• Molecular Biology
• Oncology

Background:

• Selective estrogen receptor modulators (SERMs) are a class of compounds that interact with the estrogen receptor (ER).
• SERM activity is determined by their molecular structure and interactions within target cells, leading to tissue-specific effects.
• Early SERMs like clomiphene citrate and tamoxifen demonstrated estrogenic and anti-estrogenic properties, respectively.

Purpose of the Study:

• To reassess the concept of SERMs based on recent clinical data.
• To discuss the molecular mechanisms underlying SERM activity.
• To review the diverse clinical applications and tissue-specific actions of various SERMs.

Main Methods:

• Review of clinical data and molecular mechanisms of SERMs.
• Discussion of early SERMs (clomiphene citrate, tamoxifen) and their applications.
• Overview of newer SERMs (raloxifene, arzoxifene, lasofoxifene, etc.) and their development.

Main Results:

• SERMs bind to the ER, inducing conformational changes that affect gene transcription.
• SERMs exhibit unique estrogenic and anti-estrogenic effects in a tissue-dependent manner.
• A wide range of SERMs have been developed with diverse clinical profiles affecting breast, bone, and cardiovascular markers.

Conclusions:

• Each SERM possesses a distinct set of clinical activities.
• The tissue-selective actions of SERMs necessitate individual evaluation for each clinical endpoint.
• Appropriate clinical trials are essential to establish definitive conclusions for each specific SERM.